HUTCHMED Reports Positive Phase III Sovleplenib Results in wAIHA
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
Autoimmune Disease
Advertisement
Sanofi’s Tzield Gains FDA Approval in Stage 3 Type 1 Diabetes
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
Akeso Wins NMPA Approval for Gumokimab in Plaque Psoriasis
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
Roche’s Tecentriq Receives FDA Priority Review for Stage III Colon Cancer
BASEL, Switzerland, June 11, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
DKSH and BridgeBio Partner to Expand ATTR-CM Treatment Access
SINGAPORE, June 11, 2026 DKSH Healthcare and BridgeBio have entered into a strategic distribution and commercialization partnership aimed at...
Advertisements
Takeda’s Zasocitinib Outperforms Deucravacitinib in Psoriasis
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
Johnson & Johnson’s IMAAVY Delivers Breakthrough Results in wAIHA
STOCKHOLM, Sweden, June 11, 2026 Johnson & Johnson has reported positive pivotal Phase 2/3 results for IMAAVY® (nipocalimab-aahu) in...
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
NEW YORK, June 9, 2026 Formation Bio announced the first participant has been dosed in a Phase 1 first-in-human...
Kyowa Kirin Highlights Vision 2030 in Integrated Report
Tokyo, Japan – June 9, 2026 Kyowa Kirin Co., Ltd. has published its Integrated Report 2025, outlining the company’s...
Antengene Secures China IND Clearance for ATG-201
SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...
Advertisement
